BKYI BIO KEY INTERNATIONAL INC
Services-Prepackaged Software · Nasdaq · SEC CIK 1019034 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.0%
TTM net income YoY-40.1%
TTM EPS YoY—
Revenue 3-yr CAGR-4.8%
Net income 3-yr CAGR—
Margins
Gross margin84.4%
Operating margin-86.2%
Net margin-89.8%
FCF margin-67.5%
EBITDA margin-85.3%
Returns
ROE-94.7%
ROA-62.8%
ROIC (approx.)-108.5%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets26.0%
Debt / equity0.00x
Current ratio2.47x
Interest coverage-129.12x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.94M | $6.93M |
| Cost of revenue | $1.37M | $1.29M |
| Gross profit | $4.56M | $5.64M |
| R&D expense | $2.61M | $2.51M |
| SG&A expense | $6.28M | $7.14M |
| Operating income | -$6.83M | -$4.01M |
| Interest expense | $60,793 | $175,755 |
| Pretax income | -$7.14M | -$4.32M |
| Income tax | $16,500 | -$22,998 |
| Net income | -$7.16M | -$4.30M |
| EBITDA | -$6.74M | -$3.92M |
| EPS (basic) | -10.77 | -20.88 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $2.69M | $437,604 |
| Receivables | $1.22M | $718,229 |
| Inventory | $370,879 | $378,307 |
| Current assets | $4.54M | $1.89M |
| PP&E, net | $67,751 | $140,198 |
| Intangibles | $830,357 | $1.10M |
| Total assets | $8.30M | $8.62M |
| Current liabilities | $3.10M | $4.55M |
| Long-term debt | — | $44,762 |
| Total debt | — | $44,762 |
| Total liabilities | $3.20M | $4.84M |
| Shareholders' equity | $5.11M | $3.77M |
| Net debt | — | -$392,842 |
| Shares outstanding | 1.09M | 371,696 |
| Cash flow statement | ||
| Operating cash flow | -$4.67M | -$2.91M |
| Capital expenditure | $12,012 | $13,047 |
| Free cash flow | -$4.68M | -$2.93M |
| Investing cash flow | -$12,012 | -$13,047 |
| Financing cash flow | $6.91M | $2.83M |
| Depreciation & amortization | $84,458 | $93,026 |
| Stock-based compensation | $166,575 | $243,250 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.